However, the median survival of patients with metastatic pancreatic cancer remains poor and is less than 6 months. This chapter gives an overview of the various monotherapy and combination chemotherapy regimens that have been evaluated in this disease, discusses the studies which have incorporated ...
Adsay NV, El-Rayes BF, Philip PA: Pancreatic cancer: The evolving role of systemic therapy. Expert Opin Pharmacother 2:1939-1947, 2001B. F. El-Rayes, N. V. Adsay, and P. A. Philip. Pancreatic cancer: the evolving role of systemic therapy. Expert Opin. Pharma cother. 2:1939Y1947...
A recent multicentre trial evaluated the use of gemcitabine plus cisplatin in such patients but the results were disappointing. What is the future of systemic therapy for advanced penile cancer?doi:10.1038/nrurol.2015.30Sharma, PranavSpiess, Philippe E.Nature Reviews Urology...
Alexiera-Figusch J, van Gilse HA, Hop WCJ, et al. Progestin therapy in advanced breast cancer: megestrol acetate - an evaluation of 160 treated cases. Cancer 46: 2369, 1980 ArticleGoogle Scholar Allegra J, Lippman M, Thompson E, et al. Oestrogen receptor status: an important variable in ...
Latest Conference Coverage Physical Functioning Measures May Predict Survival Outcomes, ICANS Risk With CAR T-Cell Therapy in NHL First-Line Atezolizumab Is Suitable in Platinum-Based Chemotherapy Ineligible mUC Adjuvant CDK4/6 Inhibitors Lay a Solid Treatment Foundation in HR+, HER2– Breast Cancer ...
[1]Surgery remains the only known curative therapy for RCC. Most patients present with solitary renal masses; however, 10-30% will have locally advanced or metastatic disease, and over a third with initially localized cancer will relapse in distant sites. The natural history of metastatic RCC (...
diffuse type cancer 有較高之存活率 (5-year survival 26% vs 16%)。手術 後輔助性化學治療,截至目前為止並非胃癌手後的常規治療。 對復發或轉移的胃癌,如果產生 gastric outlet obstruction 可考慮進行 palliative surgery。全身性化學治療的目的在控制腫瘤生長並緩解腫瘤引起的 ...
Adjuvant systemic therapy in breast cancer: A review. Eur J Cancer Clin Oncol 1983; 19:1753-1770.Mouridsen HT: Adjuvant systemic therapy in breast cancer. Eur J Cancer 29 (A): 595-598, 1993Mouridsen HT: Adjuvant systemic therapy in breast cancer. Eur J Cancer 29(A): 595–598, 1993...
Cancer Immunol. Immunother. 66, 1437–1447 (2017). Article CAS PubMed PubMed Central Google Scholar Larsson, A. M., Roxå, A., Leandersson, K. & Bergenfelz, C. Impact of systemic therapy on circulating leukocyte populations in patients with metastatic breast cancer. Sci. Rep. 9, ...
Clin. Cancer Res. 26, 4643–4650 (2020). Article CAS PubMed PubMed Central Google Scholar Senan, S. et al. PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non...